Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial 
- Ann. Oncol., Volume 30, Issue 5, May 2019, Pages 788-795 | https://doi.org/10.1093/annonc/mdz058